Help move atopic dermatitis care forward:

Key Exclusion Criteria

Individuals meeting any of the following conditions will not be eligible to participate:

• Are pregnant or breast-feeding or are planning to become pregnant during the duration of the study for 90 days following the final dose of study drug.
• Had a malignancy within the last 5 years, with the exception of successfully treated basal cell carcinoma.
• Have clinically significant abnormalities in any of the clinical laboratory evaluations at screening or baseline as determined by the study doctor.
• Are using any medications that may interfere with the study drug, its absorption, metabolism or the assessment of study results.
• Have a history of alcohol abuse and/or illicit drug use within 12 months prior to dosing.
• Have any uncontrolled current or recurrent illness (e.g., hepatitis B surface antigen, hepatitis C virus, or other condition) that could affect:
  • The action, absorption or disposition of the investigational product;
  • Clinical or laboratory assessments; or
  • Participant safety, including any significant concomitant disorder, major clinically significant depression as deemed by the study doctor, active bacterial, fungal, or viral infection, incompatible with participation in the study.
• Have the presence of any skin conditions (e.g., psoriasis, seborrheic dermatitis) or have large tattoos that would interfere with clinical assessment, evaluation of AD, or treatment response.
• Have an ongoing clinically significant skin infection or is receiving treatment for infection that may interfere with assessment of AD.